Press Releases

Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

RICHMOND, Calif., Nov. 10, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate in the following conferences in November.

  • Jefferies 2016 London Healthcare Conference, London, UK, November 16-17, 2016
    Dr. Macrae will present an update on the Company's therapeutic development programs on Thursday, November 17th at 2:00 pm GMT. The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentation for two weeks after the event.
  • 28th Annual Piper Jaffray Healthcare Conference, New York, NY, November 29-30, 2016
    Dr. Macrae will participate in a panel discussion on Tuesday, November 29th at 3:00 pm ET. Webcasting services are not provided for this session.

About Sangamo
Sangamo BioSciences, Inc. is focused on Pioneering Genetic Cures for monogenic and infectious diseases by deploying its AAV-based gene therapy platform, and therapeutic genome editing and gene regulation platforms based on its novel zinc finger DNA-binding protein technology. The Company's proprietary zinc finger nuclease (ZFN)-mediated in vivo genome editing approach is focused on monogenic diseases, including hemophilia and lysosomal storage disorders MPS I and MPS II. Sangamo has initiated a Phase 1/2 clinical trial for hemophilia B, the first in vivo genome editing application cleared by the FDA. In addition, Sangamo has Phase 1/2 and Phase 2 clinical programs in HIV/AIDS (SB-728). The Company has also formed a strategic collaboration with Biogen Inc. for hemoglobinopathies, including sickle cell disease and beta-thalassemia, and with Shire International GmbH to develop therapeutics for Huntington's disease. It has established strategic partnerships with companies in non-therapeutic applications of its technology, including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the Company's website at

Sangamo BioSciences, Inc. (PRNewsFoto/Sangamo BioSciences, Inc.)

Logo -


To view the original version on PR Newswire, visit:

SOURCE Sangamo BioSciences, Inc.

Sign Up For E-Mail Alerts

Sign Up